Nihon Pharmaceutical

Focus: Nihon Pharmaceutical is a Japan-based specialty pharma focused on plasma fractions and anti-spasmodic drugs with deep expertise in rare diseases. The company operates from Osaka with a concentrated pipeline in neurological and immunological conditions.

Rare Diseases

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Nihon Pharmaceutical

AI assessmentNot Hiring

No open roles listed right now. Follow Nihon Pharmaceutical to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthStrong

Pipeline

Late-stage

14 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

NPF-08

Healthy Volunteers

Phase 1/2

Clinical Trials (1)

NCT03423771Phase I/II Clinical Trial of NPF-08 in Healthy Volunteers

Phase 1/2

Help build intelligence for Nihon Pharmaceutical

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Heavy Phase 3 pipeline (14 programs) across high-unmet-need rare diseases including Guillain-Barré Syndrome, CIDP, and autoimmune encephalitis—multiple near-term catalysts
Platform expertise in immunoglobulin and plasma-derived therapies positions the company as a niche player in underserved neurological indications
Osaka headquarters offers entry into Japanese pharma with global rare disease focus

Watch Out For

Zero active job openings signals no active hiring or organizational contraction—unclear hiring trajectory and team size
Limited public financial data (no revenue, R&D spend, or cash position disclosed) creates uncertainty around runway and sustainability
No recent news, publications (0), or FDA warnings on file limit visibility into scientific output and regulatory standing

Generated by Claude from Nihon Pharmaceutical's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

NPB-01

Bullous Pemphigoid

Phase 2

Clinical Trials (1)

NCT00809822Clinical Trial of NPB-01 in Patients With Bullous Pemphigoid Unresponsive to Corticosteroids.

Phase 2

NPO-13: l-menthol

Bowel Disease

Phase 2

Clinical Trials (1)

NCT04097574Study of NPO-13 During Colonoscopy

Phase 2

NPB-01

Neuromyelitis Optica Spectrum Disorder

Phase 2

Clinical Trials (1)

NCT01845584Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy.

Phase 2

NPO-13

Bowel Disease

Phase 2

Clinical Trials (1)

NCT02265939Phase Ⅱ Dose Response Study of NPO-13 in Patients Undergoing Total Colonoscopy

Phase 2

NPO-11

Patients Undergoing Gastric Endoscopy

Phase 3

Clinical Trials (1)

NCT00742599Phase III Controlled Clinical Study of NPO-11 in Patients Undergoing Gastric Endoscopy